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This study examines the efﬁcacy and toxicity of two stereotactic body radiation therapy
(SBRT) dose regimens for treatment of early prostate cancer. Forty-one patients treated
with 35Gy were matched with 41 patients treated with 36.25Gy. Both patient groups
received SBRT in ﬁve fractions over ﬁve consecutive days using the CyberKnife. Each group
had 37 low-risk patients and 4 intermediate-risk patients. No statistically signiﬁcant differ-
ences were present for age, prostate volume, PSA, Gleason score, stage, or risk between
the groups. The dose was prescribed to the 83–87% isodose line to cover the prostate
and a 5-mm margin all around, except 3mm posteriorly. The overall median follow-up is
51months (range, 45–58months) with a median 54 and 48months follow-up for the 35
and 36.25-Gy dose groups, respectively. One biochemical failure occurred in each group
yielding a 97.5% freedom from biochemical failure. The PSA response has been favorable
for all patients with a mean PSA of 0.1 ng/ml at 4-years. Overall toxicity has been mild
with 5% late grade 2 rectal toxicity in both dose groups. Late grade 1 urinary toxicity was
equivalent between groups; grade 2 urinary toxicity was 5% (2/41 patients) and 10% (4/41
patients) in the 35-Gy and 36.25-Gy dose groups (p= 0.6969), respectively. Overall, the
highly favorable PSA response, limited biochemical failures, limited toxicity, and limited
impact on quality of life in these low- to low-intermediate-risk patients are supportive of
excellent long-term results for CyberKnife delivered SBRT.
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INTRODUCTION
As has been seen for other malignancies such as lung, liver, spine,
and kidney (Svedman et al., 2008; Gagnon et al., 2009; Rusthoven
et al., 2009; Martin and Gaya, 2010; Timmerman et al., 2010),
evidence is rapidly accumulating that supports acceptable disease
control and acute and late toxicity of stereotactic body radiother-
apy (SBRT) for low-risk prostate cancer (Friedland et al., 2009;
King et al., 2009; Bolzicco et al., 2010; Fuller et al., 2010; Jabbari
et al., 2010; Katz et al., 2010; Meier et al., 2010; Boike et al., 2011;
Freeman and King, 2011; Townsend et al., 2011). Indeed, initial
studies on low-risk patients support SBRT’s potential for clinical
efﬁcacy while limiting treatment-relatedmorbidity andmaintain-
ing quality of life (QOL; Friedland et al., 2009; King et al., 2009;
Katz et al., 2010). Longer-term results report 93% biochemical
control at a median 5 years follow-up (Freeman and King, 2011).
Additional publications with varying follow-up lengths, numbers
of patients, and risk categories continue to support these ﬁnd-
ings (Bolzicco et al., 2010; Jabbari et al., 2010; Boike et al., 2011;
Townsend et al., 2011). Furthermore, industry sponsored multi-
institution clinical studies have reported promising preliminary
results (Fuller et al., 2010; Meier et al., 2010).
Stereotactic body radiotherapy delivers a large radiation dose
in few fractions, typically four to ﬁve fractions of 7–10Gy. This
approach takes advantage of the prostate’s low α/β ratio. While
debate continues on the exact value of the α/β ratio evidence
from a variety of sources suggest that the α/β ratio resides in the
1.4- to 1.5-Gy range (Brenner and Hall, 1999; Fowler et al., 2001,
2003; King and Fowler, 2001; Brenner et al., 2002). Furthermore,
supporting evidence for this low α/β ratio value continues to accu-
mulate; a recent report by Miralbell et al. (2011) concluded, based
on seven datasets with over 5000 patients, that the α/β ratio for
prostate cancer is 1.4 Gy.
Given that increased dose, particularly for intermediate- and
high-risk localized prostate cancer patients, has shown improved
biochemical control and cause-speciﬁc survival for EBRT as well
as intensity-modulated radiation therapy (IMRT) and brachyther-
apy treatments (Pollack et al., 2002; Kupelian et al., 2004; Zelefsky
et al., 2006; Stone et al., 2010), the low α/β ratio of prostate
cancer offers the opportunity, via hypofractionation, for even fur-
ther dose escalation. Indeed, in the case of SBRT, assuming the
prostate α/β ratio is 1.4–1.5Gy then the equivalent dose (EQD)
for SBRT’s hypofractionated dose schemes typically range from
90.15–140Gy. Thus, SBRT offers a higher EQD1.8 than conven-
tional fractionation schemes that reside around 70Gy (Kuban
et al., 2008), dose-escalated fractionation schemes ranging up to
roughly 80Gy (Zelefsky et al., 1998, 2006; Hanks et al., 2000),
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moderate hypofractionation (Kupelian et al., 2005) at 84.8Gy, and
even “ultra-high” IMRT doses at 86.4Gy (Cahlon et al., 2008).
While long-term results are not yet available, the on-going favor-
able PSA and biochemical control results of SBRT delivered in the
90- to 96-Gy EQD1.8 range for low-risk patients are promising.
As such, the purpose of this study is to examine the toxicity, PSA
nadirs and 4-year efﬁcacy of two dose regimens for CyberKnife
delivered SBRT treatment of prostate cancer. Speciﬁcally,we exam-
ine SBRT delivery of a total dose of 35Gy (EQD1.8 91Gy) and
36.25Gy (EQD1.8 96Gy) both delivered in ﬁve daily fractions
using the CyberKnife.
MATERIALS AND METHODS
PATIENTS AND TREATMENT
Between April 2006 and July 2008, 304 patients with organ-
conﬁned prostate cancer were treated with SBRT at Winthrop
University Hospital in Mineola, NY, USA. All patients signed con-
sent statements and were informed of the potential risks involved
with this treatment. Institutional IRB-approval was obtained on
the treatment protocol. Details of the treatment have been previ-
ously published (Katz et al., 2010). Brieﬂy, a total dose of either
35 or 36.25Gy was delivered in 5Gy fractions over consecu-
tive days using CyberKnife (Accuray Inc., Sunnyvale, CA, USA)
SBRT. The planning target volume (PTV) equaled the prostate
plus a 5-mm margin (3mm posteriorly). The dose was pre-
scribed to the 83–87% isodose line covering 95% of the PTV.
The D50 to bladder and rectum were to be less than 50% of
Dmax, the D50 to the penile bulb was to be less than 45%,
there were no constraints on the urethra. All patients received
a 1500-mg amifostine enema 15min prior to each fraction after a
bowel prep that included Dulcolax ®(Boehringer Ingelheim, Ger-
many) and a Fleet Enema. Four gold ﬁducials were tracked during
each fraction, including translations and rotations, and beam aim
automatically corrected when motion was detected. Each frac-
tion was delivered in 45min with two collimators using 140–170
beams.
MATCHED PAIR
For the purposes of this report, the low dose (35Gy) patients
were matched with the higher dose (36.25Gy) patients by risk
and in the order of treatment. Only patients who had not
received neoadjuvant hormonal therapy were considered eligi-
ble for the pair matching. In addition, three patients in the
35-Gy group and three in the 36.25-Gy group who had died
from causes other than prostate cancer were excluded from the
pair matching. Speciﬁcally, each low dose patient that had not
received neoadjuvant hormonal therapy was matched with a
higher dose patient who had the same risk and who had not
received neoadjuvant hormonal therapy. The higher dose patients
were selected for pair matching in order from the time of treat-
ment. This resulted in a match of 41 patients in each dose
group.
FOLLOW-UP AND STATISTICAL ANALYSIS
All patients were scheduled for follow-up 3weeks after ﬁnal
treatment, 4months later and then every 6months thereafter.
PSA tests were performed 3 and 6months after treatment,
and every 6months thereafter. QOL was assessed using the
expanded prostate cancer index composite (EPIC) question-
naire (Wei et al., 2000) at every follow-up visit during the
ﬁrst year and every 12months thereafter. Toxicity was assessed
using the Radiation Therapy Oncology Group (RTOG) urinary
and rectal toxicity scale (Cox et al., 1995) at every follow-
up visit. Biochemical failure was assessed using the Phoenix
deﬁnition (Roach et al., 2006). Statistical independence for
patient characteristics was assessed for continuous variables using
the Student’s t -test whereas discrete variables were assessed
using the Fisher’s exact test. All statistical analysis was per-
formed using Prism (GraphPad Software, Inc., La Jolla, CA,
USA).
RESULTS
MATCHED PAIR
A total of 41 patients from each dose group were included in this
analysis. No statistically signiﬁcant differences were present for
age, baseline PSA, Gleason score, prostate volume, stage, or risk
between the two dose groups (Table 1). Speciﬁcally, each group
had 37 low-risk patients (Gleason Score 6 and PSA< 10 ng/ml)
and 4 intermediate-risk patients (Gleason Score 7 or PSA> 10
and <20 ng/ml). Median baseline PSAs were 5.46 and 5.52 ng/ml
for the low- and intermediate-risk groups, respectively. Median
ages were 70.2 and 69.8 years, respectively. The median number of
positive cores in each group was 2. The mean prostate volume was
48.23 cc (range, 28–108 cc). Dose constraints were met with the
mean D50’s 42% of Dmax for the rectum/bladder and less than
40% of Dmax for the penile bulb. The mean dose to the testes was
5.1Gy.
Table 1 | Patient characteristics detailed by overall cohort and dose.
Characteristic All patients (n=82) 35Gy group (n=41) 36.25Gy group (n=41) p-Value
Low-risk 74 37 37 1
Intermediate risk 4 4 4 1
T-STAGE
T1c 64 38 38 1
T2a 6 3 3 1
Median PSA, range (ng/ml) 5.35, 0.9–13.2 5.3, 0.9–12.05 5.4, 1.27–13.2 0.5064
Median age, range (years) 70, 45–84 71, 56–84 69, 4–84 0.7569
Median prostate volume (cc) 48.23, 28–108 49.05, 28–108 47.41, 29–104 0.821
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CLINICAL OUTCOMES
The overallmedian follow-up is 51months (range, 45–58months)
with a median 54months (range, 51–58months) and 48months
(range, 45–52months) follow-up for the 35-Gy and 36.25-Gy
dose groups, respectively. The PSA response (Figure 1) has
been favorable for all patients with a median PSA of 0.2, 0.1,
and 0.1 ng/ml at 36, 42, and 48months, respectively, with no
statistically signiﬁcant differences observed between the dose
groups at latest follow-up (p= 0.8130) or as a function of time
(p= 0.7704). To date, one biochemical failure has occurred in
each dose group. For the 35-Gy dose group a low-risk patient
failed at 50months. For the 36.25-Gy dose group a low-risk
patient failed at 36months. Both patients had distant metastases.
The resulting overall 4-year freedom from biochemical relapse is
97.5%.
TOXICITY AND QUALITY OF LIFE
Late grade 2 rectal toxicity was 5% for both groups. Late grade
2 urinary toxicity, consisting of dysuria, urgency, and inconti-
nence, occurred in 2/41 (5%) patients for the 35-Gy group and
in 4/41 (10%) patients for the 36.25-Gy group. Of those patients
that were cystoscoped prostatic urethral inﬂammation was the
cause of the symptoms. The differences in late grade rectal and
FIGURE 1 | Median PSA response over time for the 35-Gy (blue) and
36.25Gy (red) dose groups.
urinary toxicity were not statistically signiﬁcant (p= 0.8987 and
p= 0.6969, respectively). No grade 3 or 4 toxicities were observed.
Table 2 summarizes all observed late toxicity.
Figure 2plots themeanEPIC scores for bowel,urinary, and sex-
ual QOL along with patient response rates for both dose groups.
All mean EPIC QOL scores initially decreased. The mean bowel
and urinary QOL scores subsequently returned to baseline val-
ues. No statistically signiﬁcant differences over timewere observed
between dose groups for the mean bowel and sexual QOL, how-
ever, for the mean urinary QOL a small, but signiﬁcant difference
(p= 0.0001) was observed over time with the lower dose group
having a better QOL. This difference dissipated over time; com-
parison of the mean urinary QOL scores for the two dose groups
as a function of time at 36 and 48months showed no signiﬁcant
difference (p= 0.4999).
DISCUSSION
This matched pair analysis shows that at 4 years follow-up,
CyberKnife delivered SBRT produces highly promising clinical
outcomes, overall limited toxicity and minimal impact on patient
QOL, regardless of whether a total dose of 35 or 36.25Gy was
delivered for low- to low-intermediate-risk patients. While longer
follow-up is needed to conﬁrm the durability of the current clini-
cal outcomes, these results are supportive of a lowα/β ratio. Results
from Cahlon et al. (2008) using ultra-high dose IMRT to 86.4Gy
yields even higher rates of control than seen with 81Gy (Zelefsky
et al., 2006). At 4 years median follow-up with 35Gy, the results
in the current study show a similarly high freedom from relapse
to the 98% 4-year actuarial rates of Cahlon et al. (2008) and an
even lower median PSA at 0.10 ng/ml. If the α/β ratio is not 1.5Gy
but higher, say 3Gy, then the EQD1.8 at the 35Gy dose would
only be 72Gy. Yet, in order to achieve the results observed in this
study, in comparison to those obtained with delivery of 86.4Gy,
it is reasonable to assume a comparable or higher EQD1.8 was
delivered. Indeed, with an α/β ratio of 1.5 Gy, the total delivered
dose of 35Gy is equivalent to a EQD1.8 of about 91Gy, which is
consistent with the observed rates of biochemical control.
The PSA nadirs reached in both groups of the current study
are suggestive of excellent long-term outcomes (Fowler, 2005).
An increasingly large body of data in the literature supports the
predictive value of the PSA nadir (Grimm et al., 2001; Ray et al.,
2006; Alcantara et al., 2007; Stock et al., 2009; Zelefsky et al., 2009;
Lambet al., 2011). Speciﬁcally, following an analysis of 742patients
treated with brachytherapy or external beam radiotherapy, Stock
Table 2 | Summary of RTOG late toxicity.
All patients (n=82) 35Gy group (n=41) 36.25Gy group (n=41) p-Value
URINARY
Grade 0 72 37 35 0.6969
Grade 1 4 2 2
Grade 2 6 2 4
RECTAL
Grade 0 73 37 36 0.8987
Grade 1 5 2 3
Grade 2 4 2 2
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et al. (2009) found that the 5-year PSA value is prognostic. They
further found that patients with a PSA value of less than 0.2 ng/ml
were unlikely to undergo biochemical failure. Zelefsky et al. (2009)
concluded that the 2-year PSA nadir is a predictor of long-term
prostate cancer mortality. While the median follow-up in the
present study is only 4 years, the median PSA is 0.1 ng/ml with
71% of patients having a PSA value of less than 0.2 ng/ml. In
fact, it appears that not all patients have reached their ultimate
nadir, as their PSAs are still slowly dropping. These low PSA read-
ings are comparable to those achieved with high-dose-rate (HDR)
brachytherapy (Martinez et al., 2001, 2009), supporting the equiv-
alence of these hypofractionated dose schemes with HDR. It also
suggests that the results with the two dose schemes used in this
study will not diverge over time.
In terms of toxicity, observed differences in urinary toxicity
between the dose groups were not statistically signiﬁcant; late
grade 3–5 toxicity was not observed in either dose group. While
4/41 patients in the higher dose group exhibited late grade 2 uri-
nary toxicity compared with 2/41 patients in the lower dose group
(grade 1 urinary toxicity was equal between groups), the small
number of patients and relatively short follow-up does not allow
ﬁrm conclusions regarding the effect of dose on toxicity. Still, an
α/β ratio of 3Gy for the urethra suggests that the higher dose could
increase the rate of complications as the EQD1.8 rises from 72 to
78Gy. The potential for increased urinary toxicity at higher doses
should encourage careful attention to dose constraints, and per-
haps inclusion of urethral dose constraints. If biochemical control
between dose groups remains comparable with longer follow-up,
it may be possible to treat with the lower dose which may decrease
the likelihood of urinary toxicity.
It should be emphasized that this study compares two doses
that were prescribed identically, with daily fractions and coverage
of the PTV at 83–87% of the Dmax.When comparing the relative
beneﬁts and toxicities of other doses used in other studies, one
must be careful to discern how the dose prescription is deﬁned.
For instance, one must take into account that IMRT based plans
will be more homogeneous, may impose less urethral dose and
may deliver less dose to the gross tumor volume (GTV) than a
CyberKnife SBRT plan that delivers the same dose to the PTV.
Even when comparing different CyberKnife doses there is vari-
ability in how the dose prescription is deﬁned. Speciﬁcally, in this
study the prostate GTV received at least 7% more dose than the
PTV, yielding respective doses of about 37.50 and 38.75Gy. In
contrast, in a multi-institutional CyberKnife SBRT clinical study
(Meier et al., 2010), the PTV is covered at 36.25Gy, but the prostate
GTV receives at least 40Gy. Evenmore confounding to direct com-
parisons is the HDR-like dosimetry used in some centers (Fuller,
2008; Jabbari et al., 2010) whereby the prescription dose is 38Gy
delivered in four fractions, but the delivered dose to the peripheral
zone ismuchhigher and theurethra is contoured andurethral dose
constrained (Fuller, 2008; Jabbari et al., 2010).Also, in two recently
published studies patients were treated every other day (King et al.,
2009; Boike et al., 2011), which may impact the efﬁcacy and toxi-
city due to repair that may take place in the 48-h period between
fractions. Thus, while comparing the reported toxicity and out-
comes of various studies is important, it is equally important to
note the differences in both prescription dose as well as the overall
FIGURE 2 | Plots of mean EPIC quality of life over time from SBRT
treatment for the 35-Gy (solid line) and 36.25Gy (dashed line) group
for (A) urinary, (B) bowel, and (C) sexual function.
treatment planning and dose delivery since these factors can also
affect the expected outcomes.
CONCLUSION
The highly favorable PSA response, limited biochemical fail-
ures, and overall limited toxicity and impact on QOL in these
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low- to low-intermediate-risk patients, obtained regardless of the
dose delivered, are supportive of excellent long-term results for
CyberKnife delivered SBRT. A small, non-signiﬁcant increase in
the rate of late grade 2 urethral toxicity, with no increase in grade
1 toxicity, was observed in the higher dose group, but no higher
rate of biochemical disease free survival was seen. Further follow-
upwill be necessary to validate these observations with the current
data and larger populations of patients with longer follow-up
should be compared to conﬁrm these ﬁndings. Nevertheless, it
should be noted that such a trend would also be true for even
higher delivered SBRT doses. That is, treatment regimes deliver-
ing total doses of 38Gy in four fractions (Fuller et al., 2010), 40Gy
in ﬁve fractions (Meier et al., 2010), and 50Gy in ﬁve fractions
(Boike et al., 2011) may well observe higher toxicity. The question
is whether delivery of higher doses will result in a correspond-
ing improvement in disease control or if further dose escalation is
unwarranted in the population of low- to low-intermediate-risk
organ conﬁned prostate cancer patients.
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